PTHS CHANNEL THERAPEUTICS CORP

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Company to hold a conference call at 8:00 a.m. ET

DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call.

Pelthos management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

Date:

Time:

Toll Free:

International:

Conf.ID:

Thursday, November 13, 2025

8:00 a.m. Eastern Time

1-877-451-6152

1-201-389-0879

13756828

  

Webcast:        

About Pelthos Therapeutics

Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at . Follow Pelthos on and .

Contacts

Investors:

Mike Moyer

Managing Director, LifeSci Advisors, LLC

Media:

KWM Communications

Kellie Walsh



(914) 315-6072



EN
05/11/2025

Underlying

PTHSCHANNEL THERAPEUTICS CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CHANNEL THERAPEUTICS CORP

 PRESS RELEASE
Free
PTHS CHANNEL THERAPE...

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Ex...

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient ne...

December 4, 2025 1 EN
 PRESS RELEASE
Free
PTHS CHANNEL THERAPE...

Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healt...

Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that Pelthos’ CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference (the “Conference”) on December 4, 2025 at 9:30 a.m. Eastern Time at The Lotte New York Palace located at 455 Madison Avenue, New York, NY 10022. I...

December 2, 2025 1 EN
 PRESS RELEASE
Free
PTHS CHANNEL THERAPE...

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Res...

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net revenues 2,716 ZELSUVMI units prescribed by 1,169 unique prescribers in the third quarter of fiscal 2025 DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pati...

November 13, 2025 1 EN
 PRESS RELEASE
Free
PTHS CHANNEL THERAPE...

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announc...

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting childrenImpetigo affects approximately 3 million people in the U.S. every year and is among the most common bacterial skin infections seen in pediatric officesPrivate convertible n...

November 7, 2025 1 EN
 PRESS RELEASE
Free
PTHS CHANNEL THERAPE...

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on...

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 Company to hold a conference call at 8:00 a.m. ET DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to th...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch